CTLA4 and melanoma: Here, using whole-exome sequences (WESs) from pre and post melanomas and patient-matched normal tissues, we identified and functionalized somatic, recurrent mutations specific to relapsing or recurrent melanomas after anti-PD-1 ± anti-CTLA-4 therapy.